KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Deferred Taxes (2016 - 2025)

Pfizer (PFE) has disclosed Deferred Taxes for 17 consecutive years, with -$433.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Deferred Taxes fell 9.34% to -$433.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.1 billion, a 1.47% decrease, with the full-year FY2025 number at -$2.1 billion, down 1.47% from a year prior.
  • Deferred Taxes was -$433.0 million for Q4 2025 at Pfizer, up from -$765.0 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $203.0 million in Q2 2021 to a low of -$3.6 billion in Q4 2021.
  • A 5-year average of -$1.0 billion and a median of -$630.5 million in 2023 define the central range for Deferred Taxes.
  • Peak YoY movement for Deferred Taxes: surged 147.56% in 2021, then plummeted 1627.27% in 2022.
  • Pfizer's Deferred Taxes stood at -$3.6 billion in 2021, then increased by 5.84% to -$3.4 billion in 2022, then skyrocketed by 45.34% to -$1.9 billion in 2023, then soared by 78.69% to -$396.0 million in 2024, then dropped by 9.34% to -$433.0 million in 2025.
  • Per Business Quant, the three most recent readings for PFE's Deferred Taxes are -$433.0 million (Q4 2025), -$765.0 million (Q3 2025), and -$272.0 million (Q2 2025).